A Scientist's Journey to Entrepreneurship - The Story of Enleofen

Venue: Zoom
Audience: Public;Healthcare Professionals
Cost:

A Scientist's Journey to Entrepreneurship – The Story of Enleofen

In this part of the Duke-NUS Bio-Entrepreneur series, we will hear about the journey of Dr Sebastian Schaefer, Assistant Professor in Duke-NUS’ Cardiovascular and Metabolic Disorders programme. As a postdoctoral fellow, Dr Schaefer was a co-inventor for a technology that was spun out into a company, Enleofen. Dr Schaefer learned to be a successful entrepreneur on the fly. With assistance from the Duke-NUS Academic Medical Centre's (AMC’s) Joint Centre for Technology and Development, Enleofen’s R&D programme was acquired by Boehringer Ingelheim. Dr Schaefer will share his story of navigating the road to bio-entrepreneurship while balancing academic research. We invite you to join us in this webinar to learn more about finding the “right partners” within the Singapore biotech ecosystem for a successful spin-off.

Date & Time:

21 October 2020, 11:00 am – 12:00 noon (SGT)

Program:

Fireside chat

Q&A session

Sign up to this Zoom webinar now! Slots are limited. Register for Limited Seats.

Programme

Speaker Profile

Sebastian studied biochemical engineering in Erlangen, Busan, and Boston and pursued a Ph.D. in genetics at the Max Delbrück Center in Berlin. During his post-doctoral training in the Cook lab at the National Heart Centre Singapore and Duke-NUS, he investigated the role of Interleukin 11 in a range of fibro-inflammatory diseases. To translate his findings, Sebastian filed several patent applications and co-founded a start-up with funding and support from Singaporean biotech entrepreneurs. His company Enleofen Bio develops first-in-class antibody therapeutics adopting a lean and asset-centric approach. This ensures basic discoveries lead to treatments in a fast and efficient manner and academic research ultimately benefits patients. To further accelerate the program, Enleofen Bio struck a deal with the global pharmaceutical company Boehringer Ingelheim in 2020.